We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Signs Consent Decree to Resolve cGMP Problems
GSK Signs Consent Decree to Resolve cGMP Problems
April 29, 2005
GlaxoSmithKline (GSK) has reached a consent decree agreement with the FDA on manufacturing violations at GSK’s Cidra, Puerto Rico, plant that will allow the firm to begin resupplying the U.S. and foreign markets with Paxil CR and Avandamet by midyear.